Hinge Health was founded in 2014 by Daniel Perez and Gabriel Mecklenburg. According to Business Insider in October 2023, “Hinge Health is preparing for an IPO once market conditions become favorable.”
Hinge Health is a digital healthcare provider that specializes in treating musculoskeletal pain with therapy plans, wearable sensors, and health coaching. Per Forge data, Hinge Health raised $826.1 million in funding over 10 rounds. Their latest funding was raised on Oct 28, 2021, from a Series E round. Key investors include Coatue, Insight Partners, Alkeon Capital, Atomico, Tiger Global Management, Whale Rock Capital Management, 11.2 Capital, and Bessemer Venture Partners.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
| Funding Date | Round | Amount Raised | Price per Share | Post-Money Valuation 3 | Key Investors | |
|---|---|---|---|---|---|---|
| 10/28/2021 | Series E | $400MM | $77.46 | $6.2B | Coatue Management, Tiger Global Management | |
|
Price per Share
$ xx.xx
Shares Outstanding
5,163,674
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Coatue Management, Tiger Global Management
|
||||||
| 01/07/2021 | Series D | $321.54MM | $43.72 | $3.04B | 11.2 Capital, Atomico, Bessemer Venture Partners, Coatue Management, Heuristic Capital, Insight Partners, Lead Edge Capital, Quadrille, Tiger Global Management | |
|
Price per Share
$ xx.xx
Shares Outstanding
7,354,666
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
11.2 Capital, Atomico, Bessemer Venture Partners, Coatue Management, Heuristic Capital, Insight Partners, Lead Edge Capital, Quadrille, Tiger Global Management
|
||||||
| 02/04/2020 | Series C-1 | $15.28MM | $6.77 | $402.28MM | 11.2 Capital, Atomico, Bessemer Venture Partners, Heuristic Capital, Insight Partners, Lead Edge Capital, Quadrille Capital | |
|
Price per Share
$ xx.xx
Shares Outstanding
2,258,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
11.2 Capital, Atomico, Bessemer Venture Partners, Heuristic Capital, Insight Partners, Lead Edge Capital, Quadrille Capital
|
||||||
| 02/04/2020 | Series C | $75MM | $7.31 | $402.28MM | 11.2 Capital, Atomico, Bessemer Venture Partners, Heuristic Capital, Insight Partners, Lead Edge Capital, Quadrille Capital | |
|
Price per Share
$ xx.xx
Shares Outstanding
10,253,027
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
11.2 Capital, Atomico, Bessemer Venture Partners, Heuristic Capital, Insight Partners, Lead Edge Capital, Quadrille Capital
|
||||||
| 07/03/2018 | Series B | $26MM | $2.26 | $87.27MM | Insight Partners | |
|
Price per Share
$ xx.xx
Shares Outstanding
11,500,586
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Insight Partners
|
||||||
| 07/24/2017 | Series A-2 | $7.36MM | $1.04 | $24.14MM | 11.2 Capital, Atomico, Heuristic Capital Partners | |
|
Price per Share
$ xx.xx
Shares Outstanding
7,112,809
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
11.2 Capital, Atomico, Heuristic Capital Partners
|
||||||
| 07/24/2017 | Series A-1 | $807,683.36 | $0.83 | $24.14MM | 11.2 Capital, Atomico, Heuristic Capital Partners | |
|
Price per Share
$ xx.xx
Shares Outstanding
975,463
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
11.2 Capital, Atomico, Heuristic Capital Partners
|
||||||
| 04/14/2017 | Series Seed-2 | $205,913.86 | $0.42 | $4.97MM | Undisclosed Investors | |
|
Price per Share
$ xx.xx
Shares Outstanding
493,325
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
| 04/22/2016 | Series Seed-1 | $1.06MM | $0.34 | $4.23MM | Undisclosed Investors | |
|
Price per Share
$ xx.xx
Shares Outstanding
3,078,601
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
A quiet stretch in tech IPOs occurred in April and early May following the U.S. enactment of tariffs and the ensuing market volatility. In the last week, public market activity has started showing signs of life again.
See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.
| Trade Metrics | Last Funding Round | |||||||
|---|---|---|---|---|---|---|---|---|
| Company | Forge Price | Last Matched | Round | Post-Money Valuation 3 | Price Per Share | Amount Raised | ||
 | Generate Biomedicines | Not available | $ xx.xx | Series C | $2.22B | $11.85 | $399.4MM | |
 | Origin | Not available | $ xx.xx | Not available | -- | -- | -- | |
 | Affinia Therapeutics | Not available | $ xx.xx | Series C | $156.61MM | $1.62 | $40MM | |
Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.
| Company | Forge Price | Market Activity | Last Matched | |
|---|---|---|---|---|
 |
Anthropic | $259.14 -$13.84 (5.07%) | High | $xxx.xx |
 |
OpenAI | $723.12 +$0.12 (0.02%) | High | $xxx.xx |
 |
SpaceX | $601.27 +$4.10 (0.69%) | High | $xxx.xx |
 |
Anduril | $110.97 +$4.00 (3.74%) | High | $xxx.xx |
 |
Databricks | $197.65 -$0.01 (0.01%) | High | $xxx.xx |
| Company | Forge Price | Market Activity | Last Matched | |
|---|---|---|---|---|
|
Anthropic | $259.14 -$13.84 (5.07%) | High | $xxx.xx |
|
OpenAI | $723.12 +$0.12 (0.02%) | High | $xxx.xx |
|
Anduril | $110.97 +$4.00 (3.74%) | High | $xxx.xx |
|
Databricks | $197.65 -$0.01 (0.01%) | High | $xxx.xx |
 |
Figure AI | $174.00 -$20.00 (10.31%) | Limited | $xxx.xx |
Updated on: Jan 30, 2026
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
